PMC:7219429 / 2427-3636 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":38,"end":54},"obj":"Disease"},{"id":"T14","span":{"begin":58,"end":66},"obj":"Disease"},{"id":"T15","span":{"begin":146,"end":154},"obj":"Disease"},{"id":"T16","span":{"begin":636,"end":644},"obj":"Disease"},{"id":"T17","span":{"begin":874,"end":883},"obj":"Disease"},{"id":"T18","span":{"begin":1200,"end":1208},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) has led to a global pandemic disease referred to as coronavirus disease 19 (COVID-19) [1]. In such a health emergency, it is critical to find a cure and stop the pandemic. Among the potential solutions currently under investigation, a combination bitherapy consisting of the antimalarial drug, hydroxychloroquine (CLQ-OH) with the antibiotic, azithromycin (ATM) has received particular attention. Following initial reports from China indicating a potential effect of chloroquine (CLQ) [2], a preliminary clinical trial was implemented in France on a small cohort of COVID-19 patients [3]. A significant viral load reduction was observed in the 20 patients treated with CLQ-OH [3], a CLQ derivative with increased solubility in water and decreased toxicity [4]. With the aim of preventing bacterial super-infection, six additional patients in this trial also received ATM for 5 days. All these patients had undetectable viral load after 6 days [3]. Thus, although these promising data need clinical confirmation with more patients, CLQ-OH/ATM combination therapy already appears superior to CLQ alone as a first-line treatment for COVID-19."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T26","span":{"begin":70,"end":73},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T27","span":{"begin":81,"end":82},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T28","span":{"begin":169,"end":170},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T29","span":{"begin":212,"end":213},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T30","span":{"begin":303,"end":304},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T31","span":{"begin":432,"end":435},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T32","span":{"begin":515,"end":516},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T33","span":{"begin":556,"end":561},"obj":"http://purl.obolibrary.org/obo/CLO_0001236"},{"id":"T34","span":{"begin":618,"end":619},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T35","span":{"begin":659,"end":660},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T36","span":{"begin":751,"end":752},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T37","span":{"begin":840,"end":843},"obj":"http://purl.obolibrary.org/obo/PR_000001343"},{"id":"T38","span":{"begin":1173,"end":1174},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) has led to a global pandemic disease referred to as coronavirus disease 19 (COVID-19) [1]. In such a health emergency, it is critical to find a cure and stop the pandemic. Among the potential solutions currently under investigation, a combination bitherapy consisting of the antimalarial drug, hydroxychloroquine (CLQ-OH) with the antibiotic, azithromycin (ATM) has received particular attention. Following initial reports from China indicating a potential effect of chloroquine (CLQ) [2], a preliminary clinical trial was implemented in France on a small cohort of COVID-19 patients [3]. A significant viral load reduction was observed in the 20 patients treated with CLQ-OH [3], a CLQ derivative with increased solubility in water and decreased toxicity [4]. With the aim of preventing bacterial super-infection, six additional patients in this trial also received ATM for 5 days. All these patients had undetectable viral load after 6 days [3]. Thus, although these promising data need clinical confirmation with more patients, CLQ-OH/ATM combination therapy already appears superior to CLQ alone as a first-line treatment for COVID-19."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T42","span":{"begin":345,"end":357},"obj":"Chemical"},{"id":"T43","span":{"begin":358,"end":362},"obj":"Chemical"},{"id":"T44","span":{"begin":364,"end":382},"obj":"Chemical"},{"id":"T45","span":{"begin":401,"end":411},"obj":"Chemical"},{"id":"T46","span":{"begin":413,"end":425},"obj":"Chemical"},{"id":"T47","span":{"begin":427,"end":430},"obj":"Chemical"},{"id":"T48","span":{"begin":537,"end":548},"obj":"Chemical"},{"id":"T49","span":{"begin":797,"end":802},"obj":"Chemical"},{"id":"T50","span":{"begin":937,"end":940},"obj":"Chemical"},{"id":"T51","span":{"begin":1108,"end":1111},"obj":"Chemical"}],"attributes":[{"id":"A42","pred":"chebi_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/CHEBI_38068"},{"id":"A43","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A44","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A45","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A46","pred":"chebi_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A48","pred":"chebi_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_15377"},{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A51","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"}],"text":"The emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) has led to a global pandemic disease referred to as coronavirus disease 19 (COVID-19) [1]. In such a health emergency, it is critical to find a cure and stop the pandemic. Among the potential solutions currently under investigation, a combination bitherapy consisting of the antimalarial drug, hydroxychloroquine (CLQ-OH) with the antibiotic, azithromycin (ATM) has received particular attention. Following initial reports from China indicating a potential effect of chloroquine (CLQ) [2], a preliminary clinical trial was implemented in France on a small cohort of COVID-19 patients [3]. A significant viral load reduction was observed in the 20 patients treated with CLQ-OH [3], a CLQ derivative with increased solubility in water and decreased toxicity [4]. With the aim of preventing bacterial super-infection, six additional patients in this trial also received ATM for 5 days. All these patients had undetectable viral load after 6 days [3]. Thus, although these promising data need clinical confirmation with more patients, CLQ-OH/ATM combination therapy already appears superior to CLQ alone as a first-line treatment for COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T24","span":{"begin":0,"end":160},"obj":"Sentence"},{"id":"T25","span":{"begin":161,"end":241},"obj":"Sentence"},{"id":"T26","span":{"begin":242,"end":466},"obj":"Sentence"},{"id":"T27","span":{"begin":467,"end":658},"obj":"Sentence"},{"id":"T28","span":{"begin":659,"end":830},"obj":"Sentence"},{"id":"T29","span":{"begin":831,"end":952},"obj":"Sentence"},{"id":"T30","span":{"begin":953,"end":1017},"obj":"Sentence"},{"id":"T31","span":{"begin":1018,"end":1209},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) has led to a global pandemic disease referred to as coronavirus disease 19 (COVID-19) [1]. In such a health emergency, it is critical to find a cure and stop the pandemic. Among the potential solutions currently under investigation, a combination bitherapy consisting of the antimalarial drug, hydroxychloroquine (CLQ-OH) with the antibiotic, azithromycin (ATM) has received particular attention. Following initial reports from China indicating a potential effect of chloroquine (CLQ) [2], a preliminary clinical trial was implemented in France on a small cohort of COVID-19 patients [3]. A significant viral load reduction was observed in the 20 patients treated with CLQ-OH [3], a CLQ derivative with increased solubility in water and decreased toxicity [4]. With the aim of preventing bacterial super-infection, six additional patients in this trial also received ATM for 5 days. All these patients had undetectable viral load after 6 days [3]. Thus, although these promising data need clinical confirmation with more patients, CLQ-OH/ATM combination therapy already appears superior to CLQ alone as a first-line treatment for COVID-19."}

{"project":"LitCovid-PubTator","denotations":[{"id":"112","span":{"begin":38,"end":56},"obj":"Species"},{"id":"113","span":{"begin":58,"end":68},"obj":"Species"},{"id":"114","span":{"begin":645,"end":653},"obj":"Species"},{"id":"115","span":{"begin":717,"end":725},"obj":"Species"},{"id":"116","span":{"begin":900,"end":908},"obj":"Species"},{"id":"117","span":{"begin":963,"end":971},"obj":"Species"},{"id":"118","span":{"begin":1091,"end":1099},"obj":"Species"},{"id":"119","span":{"begin":364,"end":382},"obj":"Chemical"},{"id":"120","span":{"begin":384,"end":390},"obj":"Chemical"},{"id":"121","span":{"begin":413,"end":425},"obj":"Chemical"},{"id":"122","span":{"begin":427,"end":430},"obj":"Chemical"},{"id":"123","span":{"begin":537,"end":548},"obj":"Chemical"},{"id":"124","span":{"begin":550,"end":553},"obj":"Chemical"},{"id":"125","span":{"begin":739,"end":745},"obj":"Chemical"},{"id":"126","span":{"begin":753,"end":756},"obj":"Chemical"},{"id":"127","span":{"begin":797,"end":802},"obj":"Chemical"},{"id":"128","span":{"begin":1101,"end":1107},"obj":"Chemical"},{"id":"129","span":{"begin":1160,"end":1163},"obj":"Chemical"},{"id":"130","span":{"begin":122,"end":144},"obj":"Disease"},{"id":"131","span":{"begin":146,"end":154},"obj":"Disease"},{"id":"132","span":{"begin":636,"end":644},"obj":"Disease"},{"id":"133","span":{"begin":807,"end":825},"obj":"Disease"},{"id":"134","span":{"begin":858,"end":883},"obj":"Disease"},{"id":"135","span":{"begin":1200,"end":1208},"obj":"Disease"}],"attributes":[{"id":"A112","pred":"tao:has_database_id","subj":"112","obj":"Tax:2697049"},{"id":"A113","pred":"tao:has_database_id","subj":"113","obj":"Tax:2697049"},{"id":"A114","pred":"tao:has_database_id","subj":"114","obj":"Tax:9606"},{"id":"A115","pred":"tao:has_database_id","subj":"115","obj":"Tax:9606"},{"id":"A116","pred":"tao:has_database_id","subj":"116","obj":"Tax:9606"},{"id":"A117","pred":"tao:has_database_id","subj":"117","obj":"Tax:9606"},{"id":"A118","pred":"tao:has_database_id","subj":"118","obj":"Tax:9606"},{"id":"A119","pred":"tao:has_database_id","subj":"119","obj":"MESH:D006886"},{"id":"A121","pred":"tao:has_database_id","subj":"121","obj":"MESH:D017963"},{"id":"A122","pred":"tao:has_database_id","subj":"122","obj":"MESH:D017963"},{"id":"A123","pred":"tao:has_database_id","subj":"123","obj":"MESH:D002738"},{"id":"A124","pred":"tao:has_database_id","subj":"124","obj":"MESH:D002738"},{"id":"A126","pred":"tao:has_database_id","subj":"126","obj":"MESH:D002738"},{"id":"A127","pred":"tao:has_database_id","subj":"127","obj":"MESH:D014867"},{"id":"A129","pred":"tao:has_database_id","subj":"129","obj":"MESH:D002738"},{"id":"A130","pred":"tao:has_database_id","subj":"130","obj":"MESH:C000657245"},{"id":"A131","pred":"tao:has_database_id","subj":"131","obj":"MESH:C000657245"},{"id":"A132","pred":"tao:has_database_id","subj":"132","obj":"MESH:C000657245"},{"id":"A133","pred":"tao:has_database_id","subj":"133","obj":"MESH:D066126"},{"id":"A134","pred":"tao:has_database_id","subj":"134","obj":"MESH:D001424"},{"id":"A135","pred":"tao:has_database_id","subj":"135","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) has led to a global pandemic disease referred to as coronavirus disease 19 (COVID-19) [1]. In such a health emergency, it is critical to find a cure and stop the pandemic. Among the potential solutions currently under investigation, a combination bitherapy consisting of the antimalarial drug, hydroxychloroquine (CLQ-OH) with the antibiotic, azithromycin (ATM) has received particular attention. Following initial reports from China indicating a potential effect of chloroquine (CLQ) [2], a preliminary clinical trial was implemented in France on a small cohort of COVID-19 patients [3]. A significant viral load reduction was observed in the 20 patients treated with CLQ-OH [3], a CLQ derivative with increased solubility in water and decreased toxicity [4]. With the aim of preventing bacterial super-infection, six additional patients in this trial also received ATM for 5 days. All these patients had undetectable viral load after 6 days [3]. Thus, although these promising data need clinical confirmation with more patients, CLQ-OH/ATM combination therapy already appears superior to CLQ alone as a first-line treatment for COVID-19."}

{"project":"2_test","denotations":[{"id":"32405156-32015508-48150994","span":{"begin":157,"end":158},"obj":"32015508"},{"id":"32405156-32074550-48150995","span":{"begin":556,"end":557},"obj":"32074550"},{"id":"32405156-32194981-48150996","span":{"begin":827,"end":828},"obj":"32194981"},{"id":"T92857","span":{"begin":157,"end":158},"obj":"32015508"},{"id":"T20596","span":{"begin":556,"end":557},"obj":"32074550"},{"id":"T63350","span":{"begin":827,"end":828},"obj":"32194981"}],"text":"The emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) has led to a global pandemic disease referred to as coronavirus disease 19 (COVID-19) [1]. In such a health emergency, it is critical to find a cure and stop the pandemic. Among the potential solutions currently under investigation, a combination bitherapy consisting of the antimalarial drug, hydroxychloroquine (CLQ-OH) with the antibiotic, azithromycin (ATM) has received particular attention. Following initial reports from China indicating a potential effect of chloroquine (CLQ) [2], a preliminary clinical trial was implemented in France on a small cohort of COVID-19 patients [3]. A significant viral load reduction was observed in the 20 patients treated with CLQ-OH [3], a CLQ derivative with increased solubility in water and decreased toxicity [4]. With the aim of preventing bacterial super-infection, six additional patients in this trial also received ATM for 5 days. All these patients had undetectable viral load after 6 days [3]. Thus, although these promising data need clinical confirmation with more patients, CLQ-OH/ATM combination therapy already appears superior to CLQ alone as a first-line treatment for COVID-19."}